TAS 4464

Drug Profile

TAS 4464

Alternative Names: TAS4464

Latest Information Update: 17 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Taiho Pharmaceutical
  • Class Antineoplastics
  • Mechanism of Action NEDD 8 activating enzyme inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Multiple myeloma; Non-Hodgkin's lymphoma
  • Phase I Haematological malignancies; Solid tumours

Most Recent Events

  • 18 May 2017 Taiho Pharmaceutical plans an open-label, multicenter phase Ia/Ib trial for Haematological malignancies (Late-stage disease, Metastatic disease) in Japan (JapicCTI173488)
  • 18 May 2017 Phase-I clinical trials in Haematological malignancies in USA (IV) (Taiho Pharmaceutical pipeline, May 2017)
  • 18 May 2017 Phase-I clinical trials in Haematological malignancies in Japan, European Union (IV) (Taiho Pharmaceutical pipeline, May 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top